India’s Sun Pharma has sought leave to appeal a US court ruling rejecting the company’s bid for dismissal of a multidistrict antitrust lawsuit involving its troubled Ranbaxy subsidiary.

Sun Pharmaceutical Industries is back before US courts as it contests US antitrust charges filed by plaintiffs over the delayed market entry of generic versions of three major drugs.

Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.